Atea Pharmaceuticals, Inc. (AVIR)

3,6700 -0,0400 (-1,08%) Al cierre: 04:00PM EDT

Atea Pharmaceuticals, Inc.

225 Franklin Street
Suite 2100
Boston, MA 02110
United States
857 284 8891
https://ateapharma.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 75

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jean-Pierre Sommadossi Ph.D.	Founder, Chairman, CEO & President	1,04M	N/A	1956
Ms. Andrea J. Corcoran J.D.	CFO, Executive VP of Legal & Secretary	712,48k	N/A	1962
Mr. Wayne Foster CPA	Executive VP of Finance & Chief Accounting Officer	580,46k	N/A	1969
Dr. Janet M. J. Hammond M.D., Ph.D.	Chief Development Officer	789,47k	N/A	1960
Dr. Maria Arantxa Horga M.D.	Chief Medical Officer	679,58k	N/A	1968
Ms. Jonae R. Barnes	Senior Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Ariyapadi N. Krishnaraj	Vice President of Marketing	N/A	N/A	N/A
Mr. Adel Moussa Ph.D.	Executive Vice President of Chemistry	N/A	N/A	N/A
Mr. Xiao-Jian Zhou Ph.D.	Executive Vice President of Early Stage Development	N/A	N/A	N/A
Mr. John F. Vavricka	Chief Commercial Officer	581,11k	N/A	1963

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Atea Pharmaceuticals, Inc., a día 1 de septiembre de 2024, es 9. Las puntuaciones base son Auditoría: 3; Tablero: 9; Derechos de los accionistas: 8; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.